This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. http://www.researchmoz.us/cognitive-impairment-pipeline-review-h1-2015-report.html

1. Cognitive Impairment - Pipeline Review, H1 2015
Global Markets Direct’s, ‘Cognitive Impairment Pipeline Review, H1 2015’, provides an overview of the Cognitive Impairment’s
therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage
and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s
team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Cognitive Impairment products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Cognitive
Impairment pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Cognitive Impairment pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 7
list Of Figures 9
introduction 10
global Markets Direct Report Coverage 10
cognitive Impairment Overview 11
therapeutics Development 12
pipeline Products For Cognitive Impairment - Overview 12
pipeline Products For Cognitive Impairment - Comparative Analysis 13
cognitive Impairment - Therapeutics Under Development By Companies 14
cognitive Impairment - Therapeutics Under Investigation By Universities/institutes 19
cognitive Impairment - Pipeline Products Glance 20
late Stage Products 20
clinical Stage Products 21
early Stage Products 22
cognitive Impairment - Products Under Development By Companies 23
cognitive Impairment - Products Under Investigation By Universities/institutes 29
cognitive Impairment - Companies Involved In Therapeutics Development 30
abbvie Inc. 30
addex Therapeutics Ltd 31
agy Therapeutics, Inc. 32
amarantus Bioscience Holdings, Inc. 33
astrazeneca Plc 34
avineuro Pharmaceuticals, Inc. 35
boehringer Ingelheim Gmbh 36
bristol-myers Squibb Company 37
cardax Pharmaceuticals, Inc. 38
Cognitive Impairment - Pipeline Review, H1 2015

2. comentis, Inc. 39
d-pharm Ltd. 40
dart Neuroscience Llc 41
eisai Co., Ltd. 42
eli Lilly And Company 43
evotec Ag 44
f. Hoffmann-la Roche Ltd. 45
forum Pharmaceuticals Inc. 46
h. Lundbeck A/s 47
heptares Therapeutics Ltd. 48
intra-cellular Therapies, Inc. 49
iproteos S.l. 50
merck & Co., Inc. 51
mithridion, Inc. 52
mnemosyne Pharmaceuticals, Inc. 53
neuralstem, Inc. 54
novartis Ag 55
octapharma Ag 56
omeros Corporation 57
pacific Northwest Biotechnology, Llc 58
panacea Pharmaceuticals, Inc. 59
pfizer Inc. 60
pherin Pharmaceuticals, Inc. 61
sage Therapeutics 62
saniona Ab 63
sanofi 64
shire Plc 65
siena Biotech S.p.a. 66
sk Biopharmaceuticals Co., Ltd. 67
sunovion Pharmaceuticals Inc. 68
suven Life Sciences Ltd. 69
takeda Pharmaceutical Company Limited 70
teva Pharmaceutical Industries Limited 71
theratechnologies Inc. 72
upsher-smith Laboratories, Inc. 73
vicore Pharma Ab 74
virogenomics, Inc. 75
cognitive Impairment - Therapeutics Assessment 76
assessment By Monotherapy Products 76
assessment By Target 77
assessment By Mechanism Of Action 80
assessment By Route Of Administration 83
assessment By Molecule Type 85
drug Profiles 87
2-pmpa - Drug Profile 87
a-431404 - Drug Profile 88
adx-92639 - Drug Profile 89
an-761 - Drug Profile 90
ap-61 - Drug Profile 91
aqw-051 - Drug Profile 92
aut-1 - Drug Profile 93
aut-6 - Drug Profile 94
aut-9 - Drug Profile 95
avl-3288 - Drug Profile 96
avn-211 - Drug Profile 97
ban-2401 - Drug Profile 98
bca-909 - Drug Profile 100
bi-409306 - Drug Profile 102
bms-933043 - Drug Profile 103
bnc-375 - Drug Profile 104
c-21 - Drug Profile 105
cdd-0304 - Drug Profile 107
cdx-085 - Drug Profile 109
csp-1103 - Drug Profile 111
daoi-b - Drug Profile 113
dp-ndd - Drug Profile 114
drug To Agonize Muscarinic M1/m4 Receptors For Psychosis And Cognitive Impairment - Drug Profile 115
drugs To Inhibit Matrix Metalloproteinase For Dementia And Cognitive Impairment - Drug Profile 116
Cognitive Impairment - Pipeline Review, H1 2015

3. dsp-3748 - Drug Profile 117
e-1r - Drug Profile 118
eltoprazine - Drug Profile 119
encenicline Hydrochloride - Drug Profile 121
erteberel - Drug Profile 124
evt-501 - Drug Profile 125
frm-0962 - Drug Profile 126
gts-21 - Drug Profile 127
htl-9936 - Drug Profile 129
idursulfase - Drug Profile 130
immune Globulin (human) - Drug Profile 131
ipr-001 - Drug Profile 133
ipr-088 - Drug Profile 134
ipr-19 - Drug Profile 135
irdabisant - Drug Profile 136
iti-214 - Drug Profile 137
ladostigil Tartrate - Drug Profile 138
levetiracetam - Drug Profile 140
luaf-64280 - Drug Profile 141
ly-3002813 - Drug Profile 142
ns-9283 - Drug Profile 143
nsi-189 - Drug Profile 145
pan-811 - Drug Profile 146
peptide T - Drug Profile 148
pf-04958242 - Drug Profile 149
ph-15 - Drug Profile 150
pnu-120596 - Drug Profile 151
ro-4938581 - Drug Profile 152
roflumilast - Drug Profile 153
rtl-551 - Drug Profile 156
sage-547 - Drug Profile 157
sar-228810 - Drug Profile 159
sen-15924 - Drug Profile 160
skl-15508 - Drug Profile 161
small Molecule 1 For Cognitive Impairment - Drug Profile 162
small Molecule 10 For Cognitive Impairment - Drug Profile 163
small Molecule 11 For Cognitive Impairment - Drug Profile 164
small Molecule 12 For Cognitive Impairment - Drug Profile 165
small Molecule 2 For Cognitive Impairment - Drug Profile 166
small Molecule 3 For Cognitive Impairment - Drug Profile 167
small Molecule 4 For Cognitive Impairment - Drug Profile 168
small Molecule 5 For Cognitive Impairment - Drug Profile 169
small Molecule 6 For Cognitive Impairment - Drug Profile 170
small Molecule 7 For Cognitive Impairment - Drug Profile 171
small Molecule 8 For Cognitive Impairment - Drug Profile 172
small Molecule To Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 For Central Nervous System - Drug Profile 173
small Molecule To Agonize Nmda2b For Cias - Drug Profile 174
small Molecule To Antagonize Gpr12 For Obesity, Cognitive Impairments And Motor Disorders - Drug Profile 176
small Molecule To Antagonize Histamine 3 Receptor For Cognition - Drug Profile 177
small Molecule To Antagonize Nachr Alpha-4 Beta-2 For Cns Disorders - Drug Profile 178
small Molecule To Inhibit Tyrosine Phosphatase For Cognition And Schizophrenia - Drug Profile 179
small Molecule To Target Gpr151 For Cns Diseases - Drug Profile 180
small Molecule To Target Mas1 For Cognitive Impairments, Blood Pressure Abnormalities And Colon Cancer - Drug Profile 181
small Molecules For Cognitive Impairment Associated With Schizophrenia - Drug Profile 182
small Molecules To Agonize 5-ht4 Receptors For Cognitive Impairment - Drug Profile 183
small Molecules To Agonize Beta-1 Adrenergic Receptor For Cognitive Impairment - Drug Profile 184
small Molecules To Agonize Gabaa Receptor For Cognitive Impairment - Drug Profile 185
small Molecules To Agonize Nachr For Alzheimer's Disease And Cognitive Impairment - Drug Profile 186
small Molecules To Antagonize 5-ht6 Receptors For Cognitive Impairment - Drug Profile 188
small Molecules To Inhibit Tyrosine Phosphatase For Cognition And Schizophrenia - Drug Profile 189
stem Cell Therapy For Cognitive Impairment - Drug Profile 190
suvn-501 - Drug Profile 191
suvn-901 - Drug Profile 192
suvn-976 - Drug Profile 193
suvn-d-1108121 - Drug Profile 194
tak-058 - Drug Profile 195
tesamorelin Acetate - Drug Profile 196
tropisetron Hydrochloride - Drug Profile 199
Cognitive Impairment - Pipeline Review, H1 2015

4. vu-0092273 - Drug Profile 200
xamoterol Fumarate - Drug Profile 201
cognitive Impairment - Recent Pipeline Updates 202
cognitive Impairment - Dormant Projects 224
cognitive Impairment - Discontinued Products 230
cognitive Impairment - Product Development Milestones 231
featured News & Press Releases 231
appendix 236
methodology 236
coverage 236
secondary Research 236
primary Research 236
expert Panel Validation 236
contact Us 236
disclaimer 237
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Cognitive Impairment - Pipeline Review, H1 2015